ArticleInternational journal of molecular sciences2021
CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- CRIPSR-Cas for hepatitis virus: a systematic review and meta-analysis of diagnostic test accuracy studies.Frontiers in microbiology · 2025Pooled it
- Advances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review.Reviews in medical virology · 2026Review
- Enhanced detection of HBV and HCV using Cas13a-FLAP and FGoAI platforms.Chemical science · 2026Article
- CRISPR-based point-of-care diagnostics for viral hepatitis: from molecular design to clinical implementation.Frontiers in bioengineering and biotechnology · 2026Review
- Advances in Novel Detection Technologies for Occult Hepatitis B Virus Infection: Building an Ultra-Sensitive Barrier for Transfusion Safety.Microorganisms · 2025Review
- CRISPR-Cas12a-Based Isothermal Detection ofInternational journal of molecular sciences · 2025Article
- CRISPR-Cas12 Application for the Detection ofInternational journal of molecular sciences · 2025Article
- Loop-Mediated Isothermal Amplification (LAMP) for the Diagnosis of Sexually Transmitted Infections: A Review.Microbial biotechnology · 2025Review
- CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential.Computational and structural biotechnology journal · 2025Review
- Article
- CRISPR for companion diagnostics in low-resource settings.Lab on a chip · 2024Review
- Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics.Viruses · 2024Review
- A rapid visualization method for detecting rotavirus A by combining nuclear acid sequence-based amplification with the CRISPR-Cas12a assay.Journal of medical microbiology · 2024Article
- Harnessing CRISPR/Cas Systems for DNA and RNA Detection: Principles, Techniques, and Challenges.Biosensors · 2024Review
- Harnessing the power of clustered regularly interspaced short palindromic repeats (CRISPR) based microfluidics for next-generation molecular diagnostics.Molecular biology reports · 2024Review
- Detection ofFrontiers in immunology · 2024Article
- Dual Detection of Hepatitis B and C Viruses Using CRISPR-Cas Systems and Lateral Flow Assay.Journal of nucleic acids · 2024Article
- A Method for Detecting Five Carbapenemases in Bacteria Based on CRISPR-Cas12a Multiple RPA Rapid Detection Technology.Infection and drug resistance · 2024Article
- ERA-CRISPR/Cas12a system: a rapid, highly sensitive and specific assay forFrontiers in cellular and infection microbiology · 2024Article
- CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients.Emerging microbes & infections · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatitis B remains a major global public health challenge, with particularly high prevalence in medically disadvantaged western Pacific and African regions. Although clinically available technologies for the qPCR detection of HBV are well established, research on point-of-care testing has not progressed substantially. The development of a rapid, accurate point-of-care test is essential for the prevention and control of hepatitis B in medically disadvantaged rural areas. The development of the CRISPR/Cas system in nucleic acid detection has allowed for pathogen point-of-care detection. Here, we developed a rapid and accurate point-of-care assay for HBV based on LAMP-Cas12a. It innovatively solves the problem of point-of-care testing in 10 min, particularly the problem of sample nucleic acid extraction. Based on LAMP-Cas12a, visualization of the assay results is presented by both a fluorescent readout and by lateral flow test strips. The lateral flow test strip technology can achieve results visible to the naked eye, while fluorescence readout can achieve real-time high-sensitivity detection. The fluorescent readout-based Cas12a assay can achieve HBV detection with a limit of detection of 1 copy/μL within 13 min, while the lateral flow test strip technique only takes 20 min. In the evaluation of 73 clinical samples, the sensitivity and specificity of both the fluorescence readout and lateral flow test strip method were 100%, and the results of the assay were fully comparable to qPCR. The LAMP-Cas12a-based HBV assay relies on minimal equipment to provide rapid, accurate test results and low costs, providing significant practical value for point-of-care HBV detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.